Skip to content

German regulator sees no additional benefit for Eylea over Lucentis in macular edema secondary to CRVO

Germany’s Federal Joint Committee have issued a final benefit assessment in respect of Bayer’s Eylea aflibercept (VEGF Trap Eye) stating that the Regeneron Inc., drug has “no additional benefit” over Lucentis ranibizumab in the treatment of visual impairment caused by macular edema secondary to central retinal vein occlusion (CRVO). The decision was expected following a preliminary January assessment from the German government-funded Institute for Quality and Efficiency in Health Care (“IQWiG”), tasked with policing the quality and efficiency of medical processes and products. The drug, developed by Regeneron Pharmaceuticals Inc., (REGN; Tarrytown, New York), is exclusively marketed by Bayer outside the US.